AusperBio to Unveil Groundbreaking Clinical Data Updates at EASL Congress 2024

AusperBio Therapeutics Inc. and Ausper Biopharma Co., Ltd. are set to present groundbreaking clinical data updates on their molecule AHB-137 at the EASL™ Congress 2024. The Phase I trials focus on achieving a functional cure for chronic hepatitis B, a prevalent liver disease affecting millions globally. Learn more about the innovative research efforts at the official EASL™ Congress website.